AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
AYTU BIOPHARMA, INC. (Nasdaq: AYTU) filed a Current Report on Form 8-K on November 13, 2025. The filing announces the release of fiscal 2026 first quarter operational and financial results. The company is incorporated in Delaware and maintains its principal executive offices in Denver, Colorado.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification of the results' release rather than a detailed financial statement. Specific metrics are contained within the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
No material changes versus the prior comparable period are detailed in the filing text. The document references a press release for the specific operational and financial performance data.
Guidance, Outlook, and Management Commentary
Management scheduled a conference call and live audio webcast for November 13, 2025, at 4:30 p.m. Eastern time to discuss the fiscal 2026 first quarter results. The call was accessible via webcast and telephone, with a replay made available at the company's discretion. The filing explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash burn figures in the press release (Exhibit 99.1) referenced in this filing.
- Confirm the company's cash runway and liquidity position as of the end of the fiscal 2026 first quarter.
- Review the conference call transcript for updated clinical trial timelines and regulatory milestones.
- Check for any new debt covenants or financing activities disclosed in the full press release.